Fig. 2: Pooled seroconversion rates following complete primary SARS-CoV-2 vaccination in each disease subtype of hematologic malignancies. | Blood Cancer Journal

Fig. 2: Pooled seroconversion rates following complete primary SARS-CoV-2 vaccination in each disease subtype of hematologic malignancies.

From: Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis

Fig. 2

CLL chronic lymphocytic leukemia, HL Hodgkin lymphoma, Leukemia acute leukemia, MDS myelodysplastic syndrome, MM multiple myeloma, MPN myeloproliferative neoplasms, NHL non-Hodgkin lymphoma.

Back to article page